<![CDATA[ SUMITOMO PHARMA Co., Ltd. : News Releases ]]> https://www.sumitomo-pharma.com/news/ en © 2005-2026 Sumitomo Pharma Co., Ltd. Mon, 27 Apr 26 09:10:27 +0900 <![CDATA[ SUMITOMO PHARMA Co., Ltd. ]]> https://www.sumitomo-pharma.com/ https://www.sumitomo-pharma.com/assets/img/img-ogp-01.webp 4647 <![CDATA[ Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares ]]> https://www.sumitomo-pharma.com/news/20260427.html Finances/Press Releases/IR News Mon, 27 Apr 26 11:30:00 +0900 4638 <![CDATA[ Notice Regarding Determination of Issue Price, Selling Price and Other Matters ]]> https://www.sumitomo-pharma.com/news/20260420-1.html Finances/Press Releases/IR News Mon, 20 Apr 26 17:30:00 +0900 4629 <![CDATA[ Notice Regarding Issuance of New Shares and Secondary Offering of Shares ]]> https://www.sumitomo-pharma.com/news/20260408-2.html Finances/Press Releases/IR News Wed, 08 Apr 26 16:00:10 +0900 4626 <![CDATA[ Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan ]]> https://www.sumitomo-pharma.com/news/20260408-1.html Finances/Press Releases/IR News Wed, 08 Apr 26 16:00:00 +0900 4621 <![CDATA[ Sumitomo Pharma Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia ]]> https://www.sumitomo-pharma.com/news/20260330.html R&D/Press Releases/IR News Mon, 30 Mar 26 15:30:00 +0900 4617 <![CDATA[ Notice Concerning Non-operating Income Recorded in the Company’s Non-consolidated Financial Statements (Japanese GAAP) ]]> https://www.sumitomo-pharma.com/news/20260325.html Finances/Press Releases/IR News Wed, 25 Mar 26 15:30:00 +0900 4595 <![CDATA[ Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan ]]> https://www.sumitomo-pharma.com/news/20260306.html Products/Press Releases/IR News Fri, 06 Mar 26 09:00:00 +0900 4593 <![CDATA[ Posted Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Wed, 04 Mar 26 16:00:00 +0900 4580 <![CDATA[ Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions ]]> https://www.sumitomo-pharma.com/news/20260303.html Corporate/Press Releases/IR News Tue, 03 Mar 26 10:00:00 +0900 4566 <![CDATA[ Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260302.pdf Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:40 +0900 4564 <![CDATA[ Announcement of Filing of Shelf Registration Statement for Issuance of New Shares ]]> https://www.sumitomo-pharma.com/news/20260302-3.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:30 +0900 4562 <![CDATA[ Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma - ]]> https://www.sumitomo-pharma.com/news/20260302-2.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:20 +0900 4560 <![CDATA[ Sumitomo Pharma Announces Revisions to Its Financial Forecasts ]]> https://www.sumitomo-pharma.com/news/20260302-1.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:10 +0900 4558 <![CDATA[ Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) ]]> https://www.sumitomo-pharma.com/news/20260226-2.html R&D/Press Releases/IR News Thu, 26 Feb 26 15:30:10 +0900 4549 <![CDATA[ Termination of License Agreement for Selective Orexin 2 Receptor Agonist DSP‑0187 ]]> https://www.sumitomo-pharma.com/news/20260226-1.html Licensing/Press Releases/IR News Thu, 26 Feb 26 15:30:00 +0900 4540 <![CDATA[ Launch of Joint Research on a Novel Multi-Stage Malaria Vaccine by Ehime University and Sumitomo Pharma and Grant Award from the GHIT Fund ]]> https://www.sumitomo-pharma.com/news/20260220.html R&D/Press Releases/IR News Fri, 20 Feb 26 14:00:00 +0900 4537 <![CDATA[ Posted R&D Meeting [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ R&D/Press Releases/IR News Thu, 19 Feb 26 14:32:50 +0900 4531 <![CDATA[ Posted Presentation Material (R&D Meeting) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260217.pdf R&D/Press Releases/IR News Tue, 17 Feb 26 13:00:00 +0900 4529 <![CDATA[ Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY) ]]> https://www.sumitomo-pharma.com/news/20260213.html Products/Press Releases/IR News Fri, 13 Feb 26 17:20:00 +0900 4464 <![CDATA[ Posted Conference on Q3 FY2025 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Mon, 02 Feb 26 15:12:00 +0900 4432 <![CDATA[ Presentation Material (Conference on Q3 FY2025 Financial Results) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260130.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:30 +0900 4431 <![CDATA[ Supplementary Financial Data (IFRS) for the Third Quarte of the Year Ending March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260130_2.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:20 +0900 4430 <![CDATA[ Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260130_1.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:10 +0900 4425 <![CDATA[ Sumitomo Pharma Selected as “Best Website” for the Third Consecutive Year in Both All Markets and Pharmaceuticals Sector Categories of Nikko Investor Relations’ FY2025 All-Listed-Companies Website Ranking ]]> https://www.sumitomo-pharma.com/news/20251222.html Others/Press Releases/IR News Mon, 22 Dec 25 11:30:00 +0900 4415 <![CDATA[ Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025 ]]> https://www.sumitomo-pharma.com/news/20251215.html Sustainability/Press Releases/IR News Mon, 15 Dec 25 11:00:00 +0900 4413 <![CDATA[ Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ene20251209.pdf R&D/Press Releases/IR News Tue, 09 Dec 25 08:30:00 +0900 4409 <![CDATA[ Sumitomo Pharma Contributes to Relief Efforts for the Large-Scale Fire in Saganoseki, Oita City ]]> https://www.sumitomo-pharma.com/news/20251205.html Others/Press Releases/IR News Fri, 05 Dec 25 11:00:00 +0900 4406 <![CDATA[ Sumitomo Pharma Announces Personnel Change ]]> https://www.sumitomo-pharma.com/news/20251201.html Corporate/Press Releases/IR News Mon, 01 Dec 25 10:00:00 +0900 4402 <![CDATA[ Posted Conference on Q2 FY2025 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Fri, 07 Nov 25 09:00:00 +0900 4386 <![CDATA[ Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ene20251104.pdf R&D/Press Releases/IR News Tue, 04 Nov 25 08:30:00 +0900 4375 <![CDATA[ Presentation Material (Conference on Q2 FY2025 Financial Results) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20251031.pdf Finances/Press Releases/IR News Fri, 31 Oct 25 15:30:50 +0900 4374 <![CDATA[ Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20251031.2.pdf Finances/Press Releases/IR News Fri, 31 Oct 25 15:30:40 +0900 4373 <![CDATA[ Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20251031.1.pdf Finances/Press Releases/IR News Fri, 31 Oct 25 15:30:30 +0900 4372 <![CDATA[ Sumitomo Pharma Announces Variances Between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2025, and Revisions to Its Financial Forecasts for the Year Ending March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/20251031-2.html Finances/Press Releases/IR News Fri, 31 Oct 25 15:30:20 +0900 4371 <![CDATA[ (Progress of Disclosure Matters) Confirmation of Gain on Sales of Subsidiary Shares from Asian Business Split and Share Transfer to Marubeni Global Pharma, and Determination of Successor Company Outline ]]> https://www.sumitomo-pharma.com/news/20251031-1.html Corporate/Press Releases/IR News Fri, 31 Oct 25 15:30:10 +0900 4343 <![CDATA[ Posted Integrated Report 2025 ]]> https://www.sumitomo-pharma.com/ir/library/annual/ Others/IR News/Notices Tue, 21 Oct 25 09:00:00 +0900 4340 <![CDATA[ Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Wegovy Subcutaneous Injection, a Treatment for Obesity Disease, in Japan ]]> https://www.sumitomo-pharma.com/news/20251014-2.html Licensing/Press Releases/IR News Tue, 14 Oct 25 15:30:10 +0900 4338 <![CDATA[ Sumitomo Pharma Presents Latest Clinical Data on Investigational Anti-Cancer Agent Enzomenib (DSP-5336) at the 2025 Annual Meeting of the Japanese Society of Hematology (JSH) ]]> https://www.sumitomo-pharma.com/news/20251014-1.html R&D/Press Releases/IR News Tue, 14 Oct 25 15:30:00 +0900 4334 <![CDATA[ Academic Conference Presentation on the Results of Phase 1 Clinical Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) ]]> https://www.sumitomo-pharma.com/news/20251001.html R&D/Press Releases/IR News Wed, 01 Oct 25 14:00:00 +0900 4332 <![CDATA[ Japan Airlines Featured Our iPS Cell-Derived Product Transportation Project on Their Website. ]]> https://www.sumitomo-pharma.com/news/20250930-1.html Others/Notices Tue, 30 Sep 25 09:00:00 +0900 4327 <![CDATA[ Sumitomo Pharma Announces Organizational Realignments and Personnel Changes ]]> https://www.sumitomo-pharma.com/news/20250902.html Corporate/Press Releases/IR News Tue, 02 Sep 25 10:00:00 +0900 4323 <![CDATA[ Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes ]]> https://www.sumitomo-pharma.com/news/20250829.html Sustainability/Press Releases/IR News Fri, 29 Aug 25 15:30:00 +0900 4316 <![CDATA[ Posted Conference on Q1 FY2025 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Thu, 07 Aug 25 09:00:00 +0900 4311 <![CDATA[ Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan ]]> https://www.sumitomo-pharma.com/news/20250805-2.html R&D/Press Releases/IR News Tue, 05 Aug 25 11:30:10 +0900 4309 <![CDATA[ Notice Regarding the Completion of the CRAFT Regenerative Medicine and Cell Therapy Manufacturing Facility ]]> https://www.sumitomo-pharma.com/news/20250805-1.html Corporate/Press Releases/IR News Tue, 05 Aug 25 11:30:00 +0900 4306 <![CDATA[ Sumitomo Pharma Announces Organizational Realignments and Personnel Changes ]]> https://www.sumitomo-pharma.com/news/20250804.html Corporate/Press Releases/IR News Mon, 04 Aug 25 10:00:00 +0900 4300 <![CDATA[ Sumitomo Pharma's Novel TLR7 Vaccine Adjuvant Selected for the CEPI Adjuvant Library -Innovative Technology that could contribute to Pandemic Preparedness- ]]> https://www.sumitomo-pharma.com/news/20250801.html R&D/Press Releases/IR News Fri, 01 Aug 25 08:30:00 +0900 4271 <![CDATA[ Presentation Material (Conference on Q1 FY2025 Financial Results) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20250731.pdf Finances/Press Releases/IR News Thu, 31 Jul 25 15:31:20 +0900 4270 <![CDATA[ Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20250731.2.pdf Finances/Press Releases/IR News Thu, 31 Jul 25 15:31:10 +0900 4269 <![CDATA[ Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20250731.1.pdf Finances/Press Releases/IR News Thu, 31 Jul 25 15:31:00 +0900